Proof of Concept Study of Vorinostat, A Histone Deacetylase Inhibitor, in Patients With Class 2 High Risk Uveal Melanoma

Trial Profile

Proof of Concept Study of Vorinostat, A Histone Deacetylase Inhibitor, in Patients With Class 2 High Risk Uveal Melanoma

Not yet recruiting
Phase of Trial: Phase 0

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Uveal melanoma
  • Focus Pharmacodynamics; Proof of concept
  • Most Recent Events

    • 04 Dec 2017 Planned End Date changed from 1 Oct 2024 to 1 Mar 2025.
    • 04 Dec 2017 Planned primary completion date changed from 1 Oct 2019 to 1 Mar 2020.
    • 04 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top